Evidence map›Paper›PMID 28819280›Full record

ArticleLeukemia2018

Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia.

N Toft, H Birgens, J Abrahamsson, L Griškevičius, H Hallböök, M Heyman, T W Klausen, Ó G Jónsson, K Palk, K Pruunsild and 9 more

5 registry-linked trialsAbstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 225 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
225citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03911128 recruitingnot on this mapstarted 2019, after this paper: background citation

A Treatment Study Protocol of the ALLTogether Consortium for Infants, Children and Young Adults (0-45 Years of Age) With Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL): a Pilot Study

TypeobservationalSponsorMats HeymanRan2019 to 2033Enrolled500ConditionsLeukemia, Acute LymphoblasticArmsObservational
NCT04307576 phase3recruitingnot on this mapstarted 2020, after this paper: background citation

ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) With Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL)

TypeinterventionalSponsorMats HeymanRan2020 to 2033Enrolled6,430ConditionsLeukemia, Acute LymphoblasticArmsOmitted Doxorubicin, Omitted Vincristine+Dexamethasone pulses, Inotuzumab Ozogamicin+Standard Maintenance Therapy, Imatinib, 6-tioguanine+Standard Maintenance Therapy
NCT06764238 phase2 / phase3recruitingnot on this mapstarted 2025, after this paper: background citation

Chinese Children's Cancer Group-2025 Protocol for Newly Diagnosed for Intermediate/High Risk Childhood B-cell ALL

TypeinterventionalSponsorInstitute of Hematology & Blood Diseases Hospital, ChinaRan2025 to 2031Enrolled1,800ConditionsAcute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)ArmsBlinatumomab (Group A), Venetoclax (nonRand Group), Blinatumomab (Group B)
NCT07246213 recruitingnot on this mapstarted 2025, after this paper: background citation

Improving Cancer Outcomes for Children, Adolescents, and Young Adults: A Multicenter Retrospective Cohort Study on Treatment Failure and Toxicity in Low- and Middle-Income Countries

TypeobservationalSponsorResonance, Inc.Ran2025 to 2028Enrolled18,000ConditionsAcute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Young Adult Cancer, Adolescent CancerArmsRetrospective Medical Record Review
NCT07502118 phase2 / phase3recruitingnot on this mapstarted 2025, after this paper: background citation

An Open-Label, Multicenter Phase 2-3 Clinical Study of Anti-CD19 Chimeric Antigen Receptor T Cells (Talikabtagene Autoleucel) in Patients With Relapsed/Refractory B-Cell Malignancies (NexCAR19)

TypeinterventionalSponsorHealth Institutes of TurkeyRan2025 to 2030Enrolled40ConditionsRelapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL), Relapsed/Refractory Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), High-grade B-cell Lymphoma (HGBCL)ArmsTalikabtagene Autoleucel
3 · Its place in the literature

Who cites it

225 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Guideline
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019
    Trial
  15. Trial
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

165 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

N ToftDepartment of Hematology, Herlev University Hospital, University of Copenhagen, Herlev, Denmark.
H BirgensDepartment of Hematology, Herlev University Hospital, University of Copenhagen, Herlev, Denmark.
J AbrahamssonDepartment of Pediatrics, Institution for Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
L GriškevičiusHematology, Oncology and Transfusion Medicine Center Vilnius University Hospital Santaros Klinikos, Vilnius University, Vilnius, Lithuania.
H HallböökDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
M HeymanChildhood Cancer Research Unit, Karolinska Institute, Astrid Lindgren's Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.
T W KlausenDepartment of Hematology, Herlev University Hospital, University of Copenhagen, Herlev, Denmark.
Ó G JónssonChildren's Hospital, Landspitali University Hospital, Reykjavík, Iceland.
K PalkDepartment of Hematology, North Estonia Medical Centre, Tallinn, Estonia.
K PruunsildTallinn Children's Hospital, Tallinn, Estonia.
P Quist-PaulsenDepartment of Hematology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.
G VaitkevicieneCentre for Pediatric Oncology and Hematology, Children's Hospital, Affiliate of Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania.
K VettenrantaDivision of Hematology-Oncology and Stem Cell Transplantation, Hospital for Children and Adolescents, Helsinki University Central Hospital, Helsinki, Finland.
A ÅsbergDepartment of Pediatrics, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.
T L FrandsenDepartment of Pediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark.
H V MarquartDepartment of Clinical Immunology, Section 7631, University Hospital Rigshospitalet, Copenhagen, Denmark.
H O MadsenDepartment of Clinical Immunology, Section 7631, University Hospital Rigshospitalet, Copenhagen, Denmark.
U Norén-NyströmDepartment of Clinical Sciences, Pediatrics, Umeå University, Umeå, Sweden.
K SchmiegelowDepartment of Pediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adults with acute lymphoblastic leukemia (ALL) do worse than children. From 7/2008 to 12/2014, Nordic and Baltic centers treated 1509 consecutive patients aged 1-45 years with Philadelphia chromosome-negative ALL according to the NOPHO ALL2008 without cranial irradiation. Overall, 1022 patients were of age 1-9 years (A), 266 were 10-17 years (B) and 221 were 18-45 years (C). Sixteen patients (three adults) died during induction. All others achieved remission after induction or 1-3 intensive blocks. Subsequently, 45 patients (12 adults) died, 122 patients relapsed (32 adults) with a median time to relapse of 1.6 years and 13 (no adult) developed a second malignancy. Median follow-up time was 4.6 years. Among the three age groups, older patients more often had higher risk ALL due to T-ALL (32%/25%/9%, P<0.001), KMT2A rearrangements (6%/5%/3%, P<0.001) and higher day 29 residual leukemia for B-lineage (P<0.001), but not T-ALL (P=0.53). Event-free survival rates (pEFS

Indexed as

AdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorChildChild, PreschoolCombined Modality TherapyFemaleHematopoietic Stem Cell TransplantationHumansInfantMaleMiddle AgedMutationPrecursor Cell Lymphoblastic Leukemia-LymphomaRemission InductionBiomarkers, Tumor

Identifiers

PMID28819280

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.